Biotech Values

[ghmm]

OCRX:

Do you know if the enriching by excluding the quick responders is a modification to the enrollment criteria after the interim or if it was existing from the start of the trial? The clinical trials record doesn't say one way or the other.
https://clinicaltrials.gov/ct2/show/NCT01966419

For those interested there were no slides on the webcast but on the website there is a June slide deck (Though the PDF has a May name) that I think Linda was referring to. Here is the direct link:
http://files.shareholder.com/downloads/ABEA-5YQ58G/0x0x825938/4D2E5766-F904-49C8-9864-F09130444F72/Ocera_Investor_Presentation_-_May_2015.pdf